Kaplan Fox Announces Investigation of Acorda Therapeutics, Inc.

NEW YORK, Nov. 15, 2017 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Acorda Therapeutics, Inc. (Nasdaq: ACOR) on behalf of investors who purchased Acorda common stock.

On November 15, 2017, Acorda announced that it has stopped enrolling new patients in its Phase 3 trial of tozadenant due to 5 deaths which occurred in the group of patients who took tozadenant. Following this disclosure, Acorda stock has declined dramatically.

Acorda also announced that it increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson's disease. According to the Company's press release, "the Company took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated with sepsis and death. Agranulocytosis is the absence of white blood cells, which fight infection. The Company also has paused new enrollment in the long-term safety studies, pending further discussion with the independent Data Safety Monitoring Board (DSMB) and the United States Food and Drug Administration (FDA)."

The Company further reported that "[i]ncluding the previously conducted Phase 2b study, approximately 890 patients have been exposed to tozadenant and 234 have been exposed to placebo. This corresponds to approximately 300 patient years of tozadenant exposure and 75 patient-years of placebo. There have been seven cases of sepsis, all in the tozadenant groups, five of which were fatal. Four of the sepsis cases were associated with agranulocytosis, two had no white blood cell counts available at the time of the event and one had a high white blood cell count."

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has decades of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP or its investigation, you may visit our website at www.kaplanfox.com. 

If you have any questions about this press release, please contact:

Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue; 14^th Floor
New York, NY 10022
(212) 687-1980
(800) 290-1952
[email protected] 
www.kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP 
350 Sansome Street, Suite 400
San Francisco, CA 94104
(415) 772-4700
[email protected]
www.kaplanfox.com

SOURCE Kaplan Fox & Kilsheimer LLP